Treatment Information

Back

Bladder Cancer treatment details. Chemotherapy.

Dana-Farber Cancer Institute, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Boston, MA
Treatments:ChemotherapyHospital:Dana-Farber Cancer Institute
Drugs:Journal:Link
Date:Feb 2012

Description:

Patients:
This study involved metastatic urothelial cancer patients who had been previously treated with a platinum-based therapy. Patients were divided into two separate treatment groups. Group A included 70 patients, 54.3% of whom were at least 65 years old and 68.6% were male. Group B had 72 patients, 45.8% of whom were at least 65 years old and 68.1% were male.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy agent vandetanib, which is an inhibitor of proteins involved in supporting blood supply to tumors.
Patients in group B were treated with docetaxel only.

Toxicities:
There was one treatment-related death due to lung infection in group A. Grade 3-4 neutropenia (14% of patients), diarrhea (7%), and rash/photosensitivity (11%) were also reported.

The most severe adverse effects in group B were of grade 4 and included grade 3-4 neutropenia (14% of patients) and infection (6%).

Results:
The median overall survival rates for groups A and B were 5.85 and 7.03 months, respectively.

Support:
This study was partially supported by the pharmaceutical company AstraZeneca.

Correspondence: Dr. Toni K. Choueiri; email: [email protected]



Back